Wanbury is currently trading at Rs. 261.75, up by 3.75 points or 1.45% from its previous closing of Rs. 258.00 on the BSE.

The scrip opened at Rs. 265.00 and has touched a high and low of Rs. 265.70 and Rs. 258.00 respectively. So far 1488 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 330.00 on 16-May-2025 and a 52 week low of Rs. 162.00 on 27-Jan-2026.

Last one week high and low of the scrip stood at Rs. 273.55 and Rs. 220.00 respectively. The current market cap of the company is Rs. 914.54 crore.

The promoters holding in the company stood at 43.02%, while Institutions and Non-Institutions held 0.59% and 56.39% respectively.

Wanbury’s (WL) Patalganga site has completed MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection successfully. Two inspectors inspected facility for three days i.e. from April 07 2026 to April 09, 2026. Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules.  

MFDS is part of PIC (Pharmaceutical inspection co-operation scheme). Company is strengthening  infrastructure by adding new state of the art manufacturing block at Andhra Pradesh site for new  APIs which under validation and commercialisation. 

Both the API manufacturing sites are USFDA approved i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations with Zero Observation. Patalganga plant received zero observation from USFDA earlier. Thereafter, Tanuku plant received Zero Observation from Anvisa (Brazil FDA).  Now again, Patalganga plant got Korea FDA Approval with Zero Observation.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.